AI Article Synopsis

  • This study investigates the early functional changes in synaptic long-term potentiation (LTP) before significant plaque formation occurs in Alzheimer's disease using a specific rat model (McGill-R-Thy1-APP transgenic rat).
  • Researchers found that the ability to induce LTP was impaired at around 3.5 months of age, persisting for 2-3 months before plaques started to form, indicating a crucial early indicator of Alzheimer's.
  • They discovered that this synaptic dysfunction was linked to reduced NMDA receptor activity, but could be temporarily reversed with targeted treatments, suggesting potential early therapeutic approaches.

Article Abstract

Long before synaptic loss occurs in Alzheimer's disease significant harbingers of disease may be detected at the functional level. Here we examined if synaptic long-term potentiation is selectively disrupted prior to extracellular deposition of Aß in a very complete model of Alzheimer's disease amyloidosis, the McGill-R-Thy1-APP transgenic rat. Longitudinal studies in freely behaving animals revealed an age-dependent, relatively rapid-onset and persistent inhibition of long-term potentiation without a change in baseline synaptic transmission in the CA1 area of the hippocampus. Thus the ability of a standard 200 Hz conditioning protocol to induce significant NMDA receptor-dependent short- and long-term potentiation was lost at about 3.5 months of age and this deficit persisted for at least another 2-3 months, when plaques start to appear. Consistent with in vitro evidence for a causal role of a selective reduction in NMDA receptor-mediated synaptic currents, the deficit in synaptic plasticity in vivo was associated with a reduction in the synaptic burst response to the conditioning stimulation and was overcome using stronger 400 Hz stimulation. Moreover, intracerebroventricular treatment for 3 days with an N-terminally directed monoclonal anti- human Aß antibody, McSA1, transiently reversed the impairment of synaptic plasticity. Similar brief treatment with the BACE1 inhibitor LY2886721 or the γ-secretase inhibitor MRK-560 was found to have a comparable short-lived ameliorative effect when tracked in individual rats. These findings provide strong evidence that endogenously generated human Aß selectively disrupts the induction of long-term potentiation in a manner that enables potential therapeutic options to be assessed longitudinally at the pre-plaque stage of Alzheimer's disease amyloidosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293804PMC
http://dx.doi.org/10.1186/s40478-014-0175-xDOI Listing

Publication Analysis

Top Keywords

long-term potentiation
16
alzheimer's disease
12
synaptic
8
freely behaving
8
disease amyloidosis
8
synaptic plasticity
8
human aß
8
longitudinal testing
4
testing hippocampal
4
hippocampal plasticity
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!